ArticleJournal of cancer research and clinical oncology2018
Variability in HER2 expression between primary colorectal cancer and corresponding metastases.
Article in Journal of cancer research and clinical oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 31 citations in OpenAlex.
- Review
- Review
- Cutaneous Metastasis of Rectal Cancer as a Diagnostic Challenge: A Clinical Case and Literature Review.Diagnostics (Basel, Switzerland) · 2024Article
- Temporal and spatial heterogeneity of HER2 status in metastatic colorectal cancer.Diagnostic pathology · 2024Article
- HER2-Positive Metastatic Colorectal Cancer.Current treatment options in oncology · 2024Review
- HER2 expression and genOmic characterization of rESected brain metastases from colorectal cancer: the HEROES study.British journal of cancer · 2024Article
- New clinical trial design in precision medicine: discovery, development and direction.Signal transduction and targeted therapy · 2024Review
- Genomic profiling of colorectal cancer in large-scale Chinese patients: amplification and somatic mutations in ERBB2.Oncology research · 2024Article
- HER2-low expression in patients with advanced or metastatic solid tumors.Annals of oncology : official journal of the European Society for Medical Oncology · 2023Article
- A comprehensive appraisal of HER2 heterogeneity in HER2-amplified and HER2-low colorectal cancer.British journal of cancer · 2023Article
- Discordance of HER2 Expression and/or Amplification on Repeat Testing.Molecular cancer therapeutics · 2023Article
- Emerging Role of ERBB2 in Targeted Therapy for Metastatic Colorectal Cancer: Signaling Pathways to Therapeutic Strategies.Cancers · 2022Review
- EGFR, HER2, and HER3 protein expression in paired primary tumor and lymph node metastasis of colorectal cancer.Scientific reports · 2022Article
- Human Epidermal Growth Factor Receptor 2 Overexpression and Amplification in Patients With Colorectal Cancer: A Large-Scale Retrospective Study in Chinese Population.Frontiers in oncology · 2022Article
- Beyond RAS and BRAF: HER2, a New Actionable Oncotarget in Advanced Colorectal Cancer.International journal of molecular sciences · 2021Review
- MACC1 regulates clathrin-mediated endocytosis and receptor recycling of transferrin receptor and EGFR in colorectal cancer.Cellular and molecular life sciences : CMLS · 2021Article
- Article
- Clinical significance of HER2 and EGFR expression in colorectal cancer patients with ovarian metastasis.BMC clinical pathology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
purposeThis study aimed to investigate the HER2 status of primary colorectal cancer (CRC) and corresponding metastases, and determine the correlation between HER2 and clinicopathological characteristics.
methodsWe collected the clinicopathological features of 98 CRC patients and 66 patients which were previously evaluated for the KRAS status. The tissue samples of primary CRC tumors (n = 98), noninvolved colorectal mucosa (n = 98), paired lymph nodes (n = 98, 69 patients had positive metastatic nodes), and liver metastases (n = 22) were evaluated using immunohistochemistry for HER2. The kappa test was used to evaluate the concordance rate of HER2 status. Survival analysis was established according to the Kaplan-Meier method.
resultsHER2 overexpression was more common in primary tumors among the younger patients (P < 0.05). No survival significance was revealed in the HER2 status. The HER2-positive rate was 11.2% for the primary CRC tumors, 0% for the normal adjacent mucosa tissues, 10.1% for the matched positive lymph nodes, and 31.8% for the corresponding metastasis. Seven of sixty-nine cases (10.1%) exhibited biomarker discordance in nodal metastases compared with primary tumors (κ = 0.48, P < 0.05); 6 out of 22 cases (27.3%) exhibited biomarker discrepancy in liver metastases compared with primary tumors (κ = 0.32, P > 0.05). Compared with lymph nodes, HER2 overexpression in the primary tissue was more common in KRAS wild-type patients (P < 0.05).
conclusionsThe present study showed a high rate of discordance in matched pairs of primary tumors and metastases, suggesting that the accurate evaluation of HER2 status is essential before any therapeutic decision.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.